P rostate cancer (PRCa) constitutes a major health issue worldwide, and is now considered one o f the most common causes of cancer death in m en.1,2 The etiology of PRCa is unclear, although current evidence suggests that PRCa is likely caused by complex interactions among genetic, endocrine and environmental factors. 3 5 Benign prostatic hyperplasia (BPH) is a nonneoplastic enlargement of the prostate. BPH is extremely common, with a rapid increase in prevalence in the fourth decade of life. According to epidemiological studies, most cancers arise in prostates with BPH (83.3%).6,7 Compared to those without BPH, men with the condition have a five-fold greater risk of developing PRCa and a four-fold greater risk of death from PRCa.8 A previous study reported that a family history of prostate disease (PRCa or BPH) was more frequendy seen in relatives of men with BPH (20%) than in relatives of men with PRCa (12.8%) or in healthy controls (5.1%). 9 In addition, in vitro malignant transformation of BPH tissue has been previously reported.10'12 W ith the increasing incidence of BPH in the ageing population, there is an urgent need for the identification of molecular markers that can serve as prognostic indicators for developing PRCa in those patients with BPH.
Androgens regulate growth and differentiation of the prostate cells through binding to a nuclear androgen receptor (AR). The A R gene is located on the long arm of the X chromosome (Xql 2-13).13 '14 The first exon of the A R gene contains two polymorphic trinucleotide repeat segments, a CAG and a GGN, which encode polyglutamine and polyglycine tracts, respectively. The number of CAG and G G N repeats varies in the general population. Longer CAG repeat lengths appear to result in reduced A R transactivational activity both in vivo and in vitro P •16 Chamberlain and coworkers15 demonstrated that the elimination of the CAG repeats in both human and rat A R resulted in a marked elevation of transcriptional activation activity. It is possible, therefore, that shorter CAG alleles result in more rapid growth of prostate cells, which in turn elevates the risk of PRCa. The functional consequences of variation in the G G N tract are less clear.
Shorter A R CAG repeats, and thus a more transcriptionally active A R , , have been associated with increased PRCa risk,7 22 progression,23 earlier age of cancer onset in white men,24,25 and aggressive early stage PRCa.18 Other investigators found no such association between short CAG alleles and PRCa.2^29 Shorter A R G G N repeats have also been associated with an increased PRCa risk,18,20,27 but other studies found no such association.22,26,28 In addition, epidemiological studies have shown that a shorter length of both CAG and GG N repeats confers a higher risk of PRCa. 18, 20 Investigators found an inverse correlation between CAG repeat length and prevalence of symptomatic BPH.30'32 Giovannucci et alA found that men with repeat lengths of 19 or less had a 76% higher incidence of BPH surgery than men with repeat lengths of 25 or more. However, another study found no association between the CAG repeat polymorphism in the A R gene and the risk of BPH.33 '34 Somatic mosaicism, triplet repeat instability (TRI) of the A R CAG repeat in somatic cells within individual PRCa patients has been previously reported.35,36 Whether instability of the CAG repeat itself conferred a growth advantage on the cells in which it occurred is not known.
We analyzed the A R , CAG and G G N repeats to determine if the length of repeats is associated with a risk of developing PRCa in patients with BPH and ifTRI of these two markers is implicated in the risk of PRCa development in BPH patients.
Methods
This study took advantage of a comprehensive populationbased health care system to identify a well-defined case-control study nested within a cohort with BPH (1974 BPH ( -1990 . Details of the study have been described previously.37 Briefly, paraffinembedded tissue samples were obtained from 28 Scottish men with biopsy proven BPH who were subsequendy diagnosed with biopsy proven PRCa at least 6 years (range, 6-15 years) after the initial BPH sample. The control group consisted of 56 men who had biopsy proven BPH (with no malignant histology) on 2 separate occasions, at least 6 years apart (range, 6-15 years). Two biopsies for each patient were examined: BPH and PRCa samples in the case population and two BPH samples in the control population. All sections were re-reviewed by two pathologists to confirm the diagnosis.
DNA extraction
DNA was extracted from the BPH sample of the case group and both BPH samples of control patients. For malignant samples, laser capture microdissection (LCM) was used to obtain tumor for DNA extraction.38,39 Normal epithelial cells were also microdissected for samples showing somatic mosaicism.
PCR amplification
PC R primers were designed to amplify a 300bp fragment around the A R CAG repeat (forward prim er 5 -T C C AGA ATC T G T T C C AGA G C G T G C -3 ' and reverse prim er 
5'F A M -G C T G T G AAG G T T G C T G T T C C T CAT-

Size determination o f markers studied
T he sizes o f PC R products and repeats num ber for A R CAG, A R G G N , H D CAG, and B A T 2 6 were determ ined using an ABI PRISM 310 Genetic Analyser (Perkin Elmer, Applied Biosystems, W arrington, UK). In cases o f samples showing T R I the range o f expanded alleles was defined as the num ber o f peaks giving more than 5% o f the height o f the m ain peak (the highest peak). 41, 42 In cases where two peaks observed at the highest point o f the trace, the m idpoint was recorded.41 T he reproducibility w ith w hich the repeat size could be determ ined was estimated by comparison o f samples between different ABI-310 runs. In each case, both the PC R amplification and the ABI-310 analysis were repeated at least twice. 
Statistical analysis
The Wilcoxon test was used to compare AR triplet repeat variation between the 1st and 2nd biopsies of patients in the case and control groups (using SPSS version 9). The M ann-W hitney test was used to determine whether there was a significant difference, according to the number of AR triplet repeats, between case and control groups (SPSS version 9). The frequency of CAG and G G N somatic changes in the case and control populations were compared statistically using the chisquare test (Minitab version 12.1, Minitab Inc., Coventry, UK). The odds ratio for risk of PRCa with AR CAG was calculated using Stata 1.0 software. The difference in proportion test (two independent samples) was used to compare the frequency of CAG TRI between case and control populations.
Results
Comparison ofAR CAG repeat length in case and control populations
CAG repeat num ber was determined in all BPH samples (for case and control groups) and in 26 (of 28 samples) o f the PRCa samples, as two malignant samples were difficult to microdissect. In these two samples the malignant foci were small and located on the edge o f the haematoxylin and eosin slide, but these foci were cut off when the sections were prepared for microdissection. In the case population, the mean CAG repeat length was 22 (range, 19-31) in the first biopsy (28 BPH samples) and 22 (range, 19-26) in the second biopsy (26 PRCa samples). In the control population, the mean CAG repeat length was 21 (range, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] in the first biopsy (56 BPH samples) and 22 (range, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] in the second biopsy (56 BPH samples).
The CAG repeat length was not significandy different between the first and second biopsies for each patient in the case (BPH to PRCa) and control (BPH to BPH) groups (P value=0.08 and 0.72, respectively). The number of CAG repeats between the first case biopsies (BPH) and the first control biopsies (BPH) failed to reach significance at the 5% level (P value=0.25). A similar finding was observed when the number of CAG repeats were compared between the second case biopsies (PRCa) and the second control biopsies (BPH) P value=0.58.
Somatic mutation for CAG repeat length was determined in 29 patients; 11 patients from the case population and 18 from the control population ( Table 1) . The difference in the CAG repeat number between the first and second biopsy for the same patient ranged from 1 to 5 repeats. The frequency of CAG somatic changes from the large to small allele was significandy higher in the case group compared to the control (/Value=0.025) and the risk of developing PRCa in BPH patients displaying this somatic mutation was 3.7 (OR=3.7, 95% 0 = 1 .1 3 to 12.15).
Comparison o f GGN repeat length in case and control populations
T he G G N repeat num ber was determ ined in all BPH samples (for case and control groups) and in only 26 (of 28 samples) PRCa samples for the same reason m entioned above. In the case population, the mean G G N repeat length was 23 (range, [16] [17] [18] [19] [20] [21] [22] [23] [24] in the first biopsies (28 BPH samples) and 23 (range, 22-24) in the second biopsies (26 PRCa samples). In the control population, the mean G G N repeat length was 23 (range, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] in the first biopsies (56 BPH samples) and 23 (range, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] in the second biopsies (56 BPH samples).
T he G G N repeat length was not significantly different between the first and second biopsies for each patient in the case (BPH to PRCa) and control (BPH to BPH) groups {P value=0.18 and 0.06, respectively). T he num ber o f G G N repeats were compared between the first case biopsies (BPH) and the first control biopsies (BPH) and the results failed to reach significance at the 5% level {P value=0.49). A similar finding was observed when the num ber o f G G N repeats were compared between the second case biopsies (PRCa) and the second control biopsies (BPH) (P value=0.94).
Somatic m utation o f the G G N repeat length was determined in 20 patients; 5 patients in the case population and 15 in the control population (Table 2 ). T he difference in the G G N repeat num ber between the first and second biopsy for the same patient ranged from 1 to 4 repeats. Results showed that there were no significant differences between the case and control groups w ith respect to G G N changes from large to small allele (P value=0.52), small to large allele (P value=0.77), or in com bined changes (all samples showing G G N somatic changes vs. all samples not showing CAG changes, P value=0.46).
Triplet repeat instability in the CAG and GGN repeats
Since the A R gene is located on the X chromosome, there is only a single allele per cell in the male; this accounts for the presence o f a single major PCR product from each specimen. Among case and control samples screened by A R G G N marker, no instability was detected. TRI was determined for the A R CAG marker in the first and the second biopsies o f 5 patients in the case population and one patient in the control (Table 3 ). D N A from microdissected normal epithelial prostate cells were obtained from case sections that showed CAG TRI (5 samples) and these samples showed no CAG instability (Table  3) . A significant difference was found between case and control populations with respect to A R CAG TRI (5 patients in the case versus 1 in the control, P value=0.008) and the O R of developing PRCa was 11.95 in patients with BPH displaying instability in the A R CAG locus (95% 0 = 1 .3 2 to 108.07). Samples showing instability for A R CAG markers were further screened with H D CAG and BAT26 markers. No instability was detected for either marker.
Discussion
Both PRCa and BPH are com m on diseases that increase in incidence with age. Previous studies have defined a significant association between BPH and developing PRCa.7 8 W ith the increasing incidence o f BPH in the ageing population, there is an urgent need for the identification o f molecular markers that can serve as prognostic indicators for developing PRCa in patients with BPH. Germ line and somatic variation in genes directly involved in regulation o f prostate cell growth might be critically im portant in understanding the carcinogenesis o f PRCa, as these variants m ight be used as diagnostic, preventative, and prognostic markers for PRCa. O u r previous studies showed that a constitutive C Y P 3 A 4 and V D R Taq\ SNPs are associated with a group o f men w ith BPH that are at an increased risk o f PRCa and may be a useful com ponent of a polygenic prediction strategy for this im portant disease.37,43,44 This study analysed the A R , CAG and G G N repeats to determine if the length/ or TRI o f repeats are associated with a risk o f developing PRCa in patients with BPH. Such an approach is likely to also lead to improvements in survival. In the converse situation, those patients who do not have a high risk o f developing PRCa could be offered standard follow-up monitoring.
T he mean num ber of CAG and G G N repeats observed in this study is consistent with previous studies where the num ber o f CAG and G G N repeats cluster around 22 and 23 respectively.20,22'24,30,31 This study showed no association between shorter CAG and G G N alleles and risk of developing PRCa. There are a number of possible factors that may have contributed to the lack of an observed association between CAG and G G N alleles and a risk of developing PRCa in this study. The effect of shorter A R alleles on PRCa, as determined in two case-control studies, is relatively small17,20 and the lack of a uniform model of analysis also makes these studies difficult to compare. Moreover, the control group used in this study were BPH patients, and A R polymorphic repeats were previously reported as associated with the development of BPH. Determining the repeat length of CAG and G G N in age-matched healthy controls would be useful to establish whether the A R polymorphic repeats were associated with development of BPH and PRCa in these groups or whether yl/? polymorphic repeat length is of no use as a prognostic marker for the development PRCa in patients with BPH.
In this smdy, somatic mutation with respect to the size of A R , CAG and G G N , markers were investigated in two different biopsies from the same patient. The results suggest that patients with CAG repeat lengths changing from a large (in the first biopsy) to a small allele (in the second biopsy) are at four times greater risk of developing PRCa than those where this does not occur (Table 1 ). This mutation might be involved in the process of developing PRCa. This smdy also showed a significant difference between the case and control population with respect to A R CAG TRI. The O R of developing PRCa in BPH patients having TRI in the A R CAG repeats was 11.95 (95% C M .3 2 to 108.07). PCR amplification of this region of the gene showed only one CAG allele from normal prostate epithelial cells. The high relative incidence o f the CAG instability in benign and tumour cells suggest that the TRI occurred in cells with a growth advantage. If the CAG instability had occurred in cells without a growth advantage, it would not have been detected, as its presence would be obscured by the proliferation of cells with a growth advantage. However, whether the CAG instability conferred a growth advantage on the cells in which it occurred is not known. Amplification of the independent polymorphic markers, H D CAG and B A T 2 6 , from benign tum our D N A was used in this smdy as a negative control as both markers play no known or suspected role in prostate neoplasia.
This smdy showed no evidence for an association between the size of A R CAG and G G N repeats and the risk of the development o f PRCa in patients with BPH. However, the results suggest that CAG somatic changes from the large to small allele might have a role in development o f PRCa. The smdy shows that a constimtive A R CAG instability is associated with a group o f men with BPH that are at an increased risk o f PRCa. This instability may be a useful component of a polygenic prediction strategy for this important disease. Although there was no obvious bias in the sample set used, the present results and conclusions might be regarded as tentative due to the relatively small sample size.
